MNMiki Nakajima

Miki Nakajima

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Miki Nakajima has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    N-Glycosylation plays a role in protein folding of human UGT1A9

    by Miki Nakajima, Toshihisa Koga, Haruko Sakai, Hiroyuki Yamanaka, Ryoichi Fujiwara, Tsuyoshi Yokoi


  • Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes

    by Tatsuki Fukami, Miki Nakajima, Taiga Maruichi, Shiori Takahashi, Masataka Takamiya, Yasuhiro Aoki, Howard L. McLeod, Tsuyoshi Yokoi

    Objective Human carboxylesterase (CES) 1A1 gene (14 exons) and CES1A3 pseudogene (six exons) are inverted and duplicated genes in a reference sequence (NT_010498). In contrast, earlier studies reported the CES1A2 gene (14 exons) instead of the CES1A3 pseudogene. The sequences of the CES1A2 gene downstream and upstream of intron 1 are identical with those of the CES1A1 and CES1A3 genes, respectively. A CES1A1 variant of which exon 1 is converted with that of the CES1A3 gene (the transcript is CES1A2) has recently been identified. We sought to clarify the confusing gene structure of human CES1A. Methods A panel of 55 human liver as well as 318 blood samples (104 Caucasians, 107 African–Americans, and 107 Japanese) was used to clarify the gene structures of CES1A1, CES1A2, and CES1A3. Real-time reverse transcription-PCR and western blot analysis were carried out. Imidapril hydrolase activity in human liver microsomes and cytosol was determined by liquid chromatography-mass spectrometry (LC-MS)/MS. Results By PCR analyses, we found that the CES1A2 gene is a variant of the CES1A3 gene. Four haplotypes, A (CES1A1 wild type and CES1A3), B (CES1A1 wild type and CES1A2), C (CES1A1 variant and CES1A3), and D (CES1A1 variant and CES1A2), were demonstrated. Ethnic differences were observed in allele frequencies of CES1A1 variant (17.3% in Caucasians and African–Americans and 25.2% in Japanese) and CES1A2 gene (14.4% in Caucasians, 5.1% in African–Americans, and 31.3% in Japanese). In human livers whose diplotype was A/A and C/C or C/D, no CES1A2 and CES1A1 mRNA was detected, respectively. In the other participants, the CES1A1 mRNA levels were higher than the CES1A2 mRNA levels. The CES1A proteins translated from CES1A1 mRNA and CES1A2 mRNA were detected in both human liver microsomes and cytosol fractions suggesting that the differences in exon 1 encoding a signal peptide did not affect the subcellular localization. Imidapril hydrolase activities reflected the CES1A protein levels. Conclusion We found that the CES1A2 gene is a variant of the CES1A3 pseudogene. The findings presented here significantly increase our understanding about the gene structure and expression properties of human CES1A.


  • Human Cytochrome P450 2A13 Efficiently Metabolizes Chemicals in Air Pollutants: Naphthalene, Styrene, and Toluene

    by Tatsuki Fukami, Miki Katoh, Hiroshi Yamazaki, Tsuyoshi Yokoi, Miki Nakajima

    Human P450 2A13 is the most efficient enzyme for catalyzing the metabolism of nicotine and metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). It is conceivable that P450 2A13 also metabolizes chemicals in air pollutants because this enzyme is highly expressed in the respiratory tract. In this study, we investigated the possibility that P450 2A13 can metabolize naphthalene, styrene, and toluene, which are included in air pollutants as well as tobacco smoke, although they were known to be metabolized by P450 1A2 or 2E1. We found that P450 2A13 catalyzed 1- and 2-naphthol formations from naphthalene with higher intrinsic clearances (kcat/Km) (3.1- and 2.2-fold, respectively) than P450 1A2 and also more efficiently catalyzed the styrene 7,8-oxide formation from styrene and the benzylalcohol formation from toluene than P450 2E1. The overlapping substrate specificity of P450 2A13 with P450 2E1 was supported by the finding that P450 2A13 catalyzed chlorzoxazone 6-hydroxylation (8-fold higher value of kcat/Km) and p-nitrophenol 2-hydroxylation (19-fold higher value of kcat/Km), which are marker activities of P450 2E1. Thus, we found that P450 2A13 metabolizes diverse environmental chemicals and has overlapping substrate specificities of P450 1A2 and 2E1, suggesting that P450 2A13 plays important roles in the local metabolism of environmental chemicals in the respiratory tract related to toxicity or carcinogenicity.


  • Open Access

    Inhibitory Effects of Neurotransmitters and Steroids on Human CYP2A6

    by Eriko Higashi, Miki Nakajima, Miki Katoh, Shogo Tokudome, Tsuyoshi Yokoi

    Human CYP2A6 catalyzes the metabolism of nicotine, cotinine, and coumarin as well as some pharmaceutical drugs. CYP2A6 is highly expressed in liver and, also, in brain and steroid-related tissues. In this study, we investigated the inhibitory effects of neurotransmitters and steroid hormones on CYP2A6 activity. We found that coumarin 7-hydroxylation and cotinine 3′-hydroxylation by recombinant CYP2A6 expressed in baculovirus-infected insect cells were competitively inhibited by tryptamine (both Ki = 0.2 μM), serotonin (Ki = 252 μM and 167 μM), dopamine (Ki = 49 μM and 22 μM), and histamine (Ki = 428 μM and 359 μM). Cotinine formation from nicotine was inhibited by tryptamine (Ki = 0.7 μM, competitive), serotonin (Ki = 272 μM, noncompetitive), dopamine, noradrenaline, and adrenaline (Ki = 11 μM, 54 μM, and 81 μM, uncompetitive). Estrogens (Ki = 0.6–3.8 μM), androgens (Ki = 60–149 μM), and corticosterone (Ki = 36 μM) also inhibited cotinine formation, but coumarin 7-hydroxylation and cotinine 3′-hydroxylation did not. Nicotine-Δ5′(1′)-iminium ion formation from nicotine was not affected by these steroid hormones, indicating that the inhibition of cotinine formation was due to the inhibitory effects on aldehyde oxidase. The nicotine-Δ5′(1′)-iminium ion formation was competitively inhibited by tryptamine (Ki = 0.3 μM), serotonin (Ki = 316 μM), dopamine (Ki = 66 μM), and histamine (Ki = 209 μM). Thus, we found that some neurotransmitters inhibit CYP2A6 activity, being related with inter- and intraindividual differences in CYP2A6-dependent metabolism. The inhibitory effects of steroid hormones on aldehyde oxidase may also contribute to interindividual differences in nicotine metabolism.


  • Open Access

    Induction of Human CYP2A6 Is Mediated by the Pregnane X Receptor with Peroxisome Proliferator-Activated Receptor-γ Coactivator 1α

    by Masahiro Itoh, Miki Nakajima, Eriko Higashi, Ryoko Yoshida, Kiyoshi Nagata, Yasushi Yamazoe, Tsuyoshi Yokoi

    CYP2A6 plays important roles in the metabolism of nicotine and some clinically used drugs. Interindividual variability in the CYP2A6 expression level in human liver might be caused by an inducible property, but the molecular mechanism of induction is unclear. Rifampicin, phenobarbital, and 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime, which are activators of pregnane X receptor (PXR) and constitutive androstane receptor (CAR), induced CYP2A6 mRNA in human hepatocytes. We identified three direct repeat separated by four nucleotides (DR4)-like elements at –6698, –5476, and –4618 in the CYP2A6 gene, to which PXR and CAR could bind after dimerization with retinoid X receptor (RXR)-α. In luciferase assays, overexpression of PXR or CAR could not activate the transcriptional activity of CYP2A6 promoter constructs (–6754 to –1) in HepG2 cells. Cotransfection of hepatocyte nuclear factor-4α did not affect the transcriptional activities in the absence or presence of PXR or CAR. Interestingly, cotransfection of peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) as well as PXR significantly enhanced the transcriptional activity (3.9-fold of control). By the deletion of a possible suppresser region (–4533 to –185), the effects of PXR/PGC-1α on the transcriptional activity were increased (6.9-fold of control). Deletion or mutation analyses revealed that two DR4-like elements at –5476 and –4618 are essential for transactivation by PXR/PGC-1α. Chromatin immunoprecipitation assay revealed that PXR and PGC-1α bind to CYP2A6 chromatin. In conclusion, we found that CYP2A6 is induced via PXR and PGC-1α through the DR4-like element at the distal response region. This is the first study to report the molecular mechanism of the induction of CYP2A6.


  • Open Access

    Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations

    by M Nakajima, T Fukami, H Yamanaka, E Higashi, H Sakai, R Yoshida, J Kwon, H Mcleod, T Yokoi

    Human cytochrome P450 (CYP) 2A6 metabolizes nicotine to cotinine and is a possible modulator of nicotine addiction. Quantitative and qualitative differences in nicotine addiction have been observed between ethnic groups. However, there are few data on the ethnic influences of the CYP2A6-nicotine metabolism relationship, particularly with regard to black subjects. We determined the nicotine metabolism and CYP2A6 genotype in 176 white subjects and 160 black subjects, comparing them with our previous data from 209 Korean subjects and 92 Japanese subjects. Large interindividual differences were observed in the cotinine/nicotine ratios in plasma calculated as an index of nicotine metabolism in white subjects (range, 0.6-36.5) and in black subjects (range, 0.9-30.4). No ethnic difference in the metabolic ratio was observed among white subjects (mean, 7.2 +/- 5.0), black subjects (mean, 7.1 +/- 4.7), and Korean subjects (mean, 8.7 +/- 11.9), whereas Japanese subjects showed a significantly (P < .005) lower metabolic ratio (mean, 3.8 +/- 3.1) compared with the other populations. Women showed significantly (P < .05) higher metabolic ratios than men in the black population (8.0 +/- 5.3 versus 6.0 +/- 3.7). Obvious ethnic differences in the CYP2A6 alleles were observed among these 4 populations. The combined frequencies of the alleles lacking or showing reduced enzymatic activity (CYP2A6*2, CYP2A6*4, CYP2A6*5, CYP2A6*7, CYP2A6*9, CYP2A6*10, CYP2A6*11, CYP2A6*17, CYP2A6*19, and CYP2A6*20) were 9.1%, 21.9%, 42.9%, and 50.5% in white, black, Korean, and Japanese subjects, respectively. These CYP2A6 alleles were associated with reduced nicotine metabolism. Among the homozygotes of CYP2A6*1, interindividual and ethnic differences in the metabolic ratio were still observed. Thus some factors other than genetic ones might also contribute to the interindividual and ethnic differences. This comprehensive study of 4 populations extends our understanding of nicotine metabolism and the impact of genetic polymorphisms of the CYP2A6 gene.


  • Open Access

    CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele

    by T Fukami, M Nakajima, H Sakai, H L McLeod, T Yokoi

    Human cytochrome P450 (CYP) 2A6 metabolizes nicotine to cotinine. Genetic polymorphisms of CYP2A6 contribute to the interindividual variability of nicotine metabolism. We encountered some subjects possessing two copies of the CYP2A6 gene, although they were genotyped as heterozygotes of the CYP2A6*4A allele (entire CYP2A6 gene deleted allele). From the subjects, we found CYP2A7 polymorphic alleles (CYP2A7*1B, CYP2A7*1C, and CYP2A7*1D) in which the sequences in the 3′-flanking region were converted to the corresponding CYP2A6 sequences, being confused with the CYP2A6*4A. These allele frequencies in European-Americans (n=187) were 1.3, 2.1, 0.3%, respectively, but these were very rare in African-Americans (n=176), Japanese (n=184), and Koreans (n=209). By an improved genotyping method, the allele frequency of CYP2A6*4A of 3.7% in European-Americans was corrected to 0%. The comprehensible and reliable genotyping method developed in this study would be useful to evaluate associations between the genotype and phenotype.


  • Isoflavones Inhibit Nicotine C‐Oxidation Catalyzed by Human CYP2A6

    by Miki Nakajima, Masahiro Itoh, Hiroyuki Yamanaka, Tatsuki Fukami, Shogo Tokudome, Yasuhiko Yamamoto, Hiroshi Yamamoto, Tsuyoshi Yokoi

    The inhibitory effects of isoflavones (daidzein, genistein, and glycitein) on human cytochrome P450 (CYP) 2A6 activities were investigated. Daidzein, genistein, and glycitein uncompetitively inhibited nicotine C‐oxidation catalyzed by recombinant CYP2A6 expressed in baculovirus‐infected insect cells with Ki values of 1.3 ± 0.3 μM, 0.7 ± 0.2 μM, and 5.2 ± 0.8 μM, respectively, but not coumarin 7‐hydroxylation. Effects of the intake of soy isoflavones on in vivo nicotine metabolism were investigated with 7 healthy Japanese homozygotes of CYP2A6*1. The cotinine/nicotine ratio of the plasma concentrations 2 hours after chewing 1 piece of nicotine gum under the basal condition (after abstaining from soy foods for 1 week) was 8.8 ± 2.6 (4.4–11.4). The ratio was significantly (P < .05) reduced to 6.7 ± 1.6 (4.0–8.2) after consumption of a soy isoflavone supplement (60 mg of total isoflavones/d) for 5 days. The authors found that isoflavone contained in soy products significantly decreased nicotine metabolism.


  • Open Access

    CHARACTERIZATION OF NOVEL CYP2A6 POLYMORPHIC ALLELES (CYP2A6*18 AND CYP2A6*19) THAT AFFECT ENZYMATIC ACTIVITY

    by Tatsuki Fukami, Miki Nakajima, Eriko Higashi, Hiroyuki Yamanaka, Haruko Sakai, Howard L. McLeod, Tsuyoshi Yokoi

    Genetic polymorphisms of CYP2A6 gene are known as a causal factor of the interindividual differences in nicotine metabolism. We found three novel CYP2A6 alleles. The CYP2A6*18A allele has a single nucleotide polymorphism (SNP) of A5668T (A1175T, Y392F) in exon 8. The CYP2A6*18B allele has synonymous SNPs of G51A (G51A), T5684C (T1191C), and T5702C (T1209C) in addition to A5668T (A1175T, Y392F). The CYP2A6*19 allele has the SNPs of A5668T (A1175T, Y392F), T6354C (intron 8), and T6558C (T1412C, I471T) as well as the conversion with the CYP2A7 sequence in the 3′-untranslated region, in which the latter two changes correspond to CYP2A6*7. Ethnic differences in the frequencies of these alleles were observed between whites, African-Americans, Japanese, and Koreans. Wild or variant CYP2A6 (CYP2A6*18, CYP2A6*19, and CYP2A6*7) were expressed in Escherichia coli. For coumarin 7-hydroxylation and 5-fluorouracil formation from tegafur, the Km values were increased, and Vmax values were decreased in CYP2A6.18 compared with those in CYP2A6.1, resulting in decreased clearance to 50 and 35% of that of the wild type, respectively. The Km and Vmax values for nicotine C-oxidation were both increased, resulting in no change of clearance. In CYP2A6.19, the effects on the coumarin 7-hydroxylation and 5-fluorouracil formation (increased Km and decreased Vmax) were prominent, resulting in decreased clearance to 8% of those of the wild type. For nicotine C-oxidation, the Km and Vmax values were both decreased, resulting in decreased clearance to 30% of that of the wild type. The changes of the kinetics in CYP2A6.19 were similar to those in CYP2A6.7. In vivo nicotine metabolism was evaluated in whites (n = 56) and Koreans (n = 40). Although the CYP2A6*18 and CYP2A6*19 alleles were found only heterozygously, a subject with CYP2A6*7/CYP2A6*19 showed a lower cotinine/nicotine ratio of the plasma concentration compared with homozygotes of the CYP2A6*1A, supporting the in vitro results that the CYP2A6*19 allele leads to decreased enzymatic activity.


  • Cancer pharmacogenomics: achievements in basic research

    by Miki Nakajima, Tsuyoshi Yokoi

    Pharmacogenomics is the study of how genetic inheritance influences the responses to drugs. Genetic polymorphisms in drug-metabolizing enzymes result in altered pharmacokinetics in therapeutic drugs. In recent years, there has been great progress in our knowledge of the effects of cytochrome P450 (CYP) polymorphisms on the pharmacokinetics of therapeutic drugs. CYP enzymes catalyze the activation or detoxification of several anticancer drugs. Anticancer drugs generally have a narrow therapeutic margin. Therefore, the interindividual variability in their efficacy and toxicity is a major problem in clinical practice. In this review, genetic polymorphisms of CYP enzymes and their clinical relevance in cancer chemotherapy are discussed.